Breaking News Instant updates and real-time market news.

UHS

Universal Health

$127.90

0.61 (0.48%)

, EHC

Encompass Health

$72.31

0.81 (1.13%)

17:09
11/15/18
11/15
17:09
11/15/18
17:09

HCA Healthcare, Encompass Health, Universal Health initiated with Buy at UBS

UBS analyst Whit Mayo launched coverage of Healthcare Facilities with a broader research note titled "Navigating an Evolving Landscape - Who Will Be Left?". The analyst is most bullish on stocks that "discount the perceived secular sector headwinds" such as Buy-rated HCA Healthcare (HCA), Encompass Health (EHC), and Universal Health (UHS), adding that investors also under-appreciate the accelerating free-cash flow profiles of these companies. Mayo differentiates HCA Healthcare based on its 0% correlation in national hospital utilization trends against public results. The analyst is also bullish on LHC Group (LHCG), stating that its same-property admission growth projections are higher than the rest. Mayo rates Community Health Systems (CYH), DaVita (DVA), and Mednax (MD) at a Sell with a bearish view of dialysis, births, and inpatient surgery end-markets. The analyst sees Community Health Systems same-property volume trend at a relatively low rate. Mayo also gives Acadia (ACHC), Amedisys (AMED), Surgery Partners (SGRY), and Tenet (THC) a Neutral rating as part of this research note based on their relative valuation as a factor of same-property volume growth.

UHS

Universal Health

$127.90

0.61 (0.48%)

EHC

Encompass Health

$72.31

0.81 (1.13%)

LHCG

LHC Group

$96.20

3.08 (3.31%)

HCA

HCA Healthcare

$137.72

-2.14 (-1.53%)

THC

Tenet

$23.70

-0.04 (-0.17%)

SGRY

Surgery Partners

$13.63

0.01 (0.07%)

AMED

Amedisys

$121.97

4.88 (4.17%)

ACHC

Acadia

$37.85

0.37 (0.99%)

DVA

DaVita

$64.64

0.26 (0.40%)

MD

Mednax

$39.81

-0.03 (-0.08%)

CYH

Community Health

$3.59

-0.11 (-2.97%)

  • 02

    Dec

  • 11

    Dec

UHS Universal Health
$127.90

0.61 (0.48%)

11/15/18
UBSW
11/15/18
INITIATION
Target $156
UBSW
Buy
Universal Health initiated with a Buy at UBS
UBS analyst Whit Mayo initiated Universal Health with a Buy rating and a price target of $156.
11/14/18
SBSH
11/14/18
NO CHANGE
Target $43
SBSH
Buy
Acadia selloff overdone, private equity the more likely buyer, says Citi
Citi analyst Ralph Giacobbe views yesterday's selloff in Acadia Healthcare (ACHC) shares as overdone. The analyst attributes the 14% pullback to headlines suggesting Universal Health (UHS) would not be a potential acquirer of the company due to potential regulatory issues. Giacobbe, however, puts "much more credence" to a private equity buyer over Universal Health. The analyst sees Acadia's Q3 results as supporting a takeover bid given the "strong" U.S. performance offset by weaker U.K., which he notes could ultimately be divested by private equity or Acadia itself. To reflect pressures in the U.K., he lowered his price target for Acadia Healthcare shares to $43 from $46. The stock closed yesterday down $5.93 to $36.01. Giacobbe keeps a Buy rating on the name.
11/13/18
RBCM
11/13/18
NO CHANGE
Target $45
RBCM
Outperform
RBC says Acadia weakness likely due to competitor note or delayed 10-Q reaction
RBC Capital analyst Frank Morgan said he suspects the intraday weakness in shares of Acadia (ACHC) was in reaction to a competitor report following a conference event, in which an analyst concluded that Universal Health (UHS) would not likely be an acquirer due to size and FTC issues. However, in his opinion, it is hard to imagine that investors would have thought a merger of these two companies was possible and Morgan believes a more likely scenario would be an LBO with a private equity sponsor or a sale of Acadia's U.K. assets. He notes that another possibility could be a delayed reaction to disclosures included in the company's 10-Q filing last week of a new False Claims investigation brought by the U.S. Attorney's Office in West Virginia. While a potential false claim investigation is always concerning, Morgan believes an investigation isolated to ancillary lab services at a limited number of facilities should likely carry less exposure, he tells investors. Morgan has an Outperform rating and $45 price target on Acadia shares.
11/13/18
FBCO
11/13/18
NO CHANGE
FBCO
Outperform
Acadia sinks, Credit Suisse sees antitrust issues with any UHS interest
After hosting Universal Health Services CFO Steve Filton for an investor dinner, Credit Suisse analyst A.J. Rice says the recovery of the company's psychiatric business is taking longer than it had originally expected. The analyst, however, adds that demand in the psych industry "is plentiful" and could support growth levels higher than the company's current targets if it can capitalize on it. Rice also opined on the recent press reports of private equity interest in Acadia Healthcare (ACHC), Universal Health Services' main public peer. If Universal Health were to look at buying Acadia, there would likely be some areas of antitrust concern, Rice tells investors in a research note. In the U.S., there could be challenges in specific markets to acquiring Acadia, while in the U.K., there would almost certainly be antitrust concerns, says the analyst. Further, Universal Health has also expressed some reluctance to consider taking on an acquisition the size of Priory in the U.K. at this time, Rice adds. Shares of Acadia Healthcare fell significantly in afternoon trading but are well off their lows. Following a few halts for volatility, the stock is down 9%, or $3.60, to $38.34. Universal Health Services, meanwhile, is down 2% to $127.71. Rice has an Outperform rating on Universal Health with a $150 price target. CNBC's David Faber last week reported that a buyout of Acadia may be a couple of weeks away.
EHC Encompass Health
$72.31

0.81 (1.13%)

11/15/18
UBSW
11/15/18
INITIATION
Target $86
UBSW
Buy
Encompass Health initiated with a Buy at UBS
UBS analyst Whit Mayo initiated Encompass Health with a Buy rating and a price target of $86.
10/11/18
SPHN
10/11/18
NO CHANGE
SPHN
Stephens says home health final rule looking like draft would weigh on providers
Stephens analyst Dana Hambly said he expects the final rule for home health reimbursement to be released by CMS in the first week of November. He is concerned that if the final rule looks similar to the draft rule, particularly regarding behavioral assumptions, it would weigh on home health stocks. For-profit, urban providers with higher percentages of therapy visits are estimated to take the largest cuts under a Patient Driven Groupings Model for reimbursement, said Hambly, who sees the impact being largest for Brookdale Senior Living (BKD) and Humana's (HUM) Kindred at Home. Others that may be impacted include Amedisys (AMED), Encompass Health (EHC), Ensign Group (ENSG) and LHC Group (LHCG).
07/26/18
07/26/18
UPGRADE
Target $87

Overweight
Encompass Health upgraded to Overweight on top-line growth potential at Piper Jaffray
As previously reported, Piper Jaffray analyst Sarah James upgraded Encompass Health to Overweight from Neutral and raised her price target on the stock to $87 from $68 following her deep dive into top-line growth opportunities and rate risk. Noting that Encompass Health is her top pick within the facility space, the analyst says its strong balance sheet gives it the opportunity to meaningfully move top-line growth through M&A. Further, James sees potential for the HH segment to increase 43% through strategically placed assets and higher collaboration rates.
07/26/18
PIPR
07/26/18
UPGRADE
PIPR
Overweight
Encompass Health upgraded to Overweight from Neutral at Piper Jaffray
LHCG LHC Group
$96.20

3.08 (3.31%)

11/15/18
UBSW
11/15/18
INITIATION
Target $109
UBSW
Buy
LHC Group initiated with a Buy at UBS
UBS analyst Whit Mayo initiated LHC Group with a Buy rating and a price target of $109.
11/01/18
WBLR
11/01/18
NO CHANGE
WBLR
Outperform
LHC Group shares could see pressure ahead of call, says William Blair
While LHC Group's organic growth trends were strong in Q3, "this was not a clean quarter," William Blair analyst Matt Larew tells investors in a post-earnings research note.The sales miss and "disconnect from expectations," which were looking for a beat-and-raise quarter, could pressure the stock ahead of today's earnings conference call, says Larew. The analyst adds that LHC's earnings release came less than an hour after the Centers for Medicare & Medicaid Services released the final 2019 home health rule. Though this looks to be largely in line with expectations, Larew contends. He keeps an Outperform rating on shares of LHC Group.
10/26/18
CHLM
10/26/18
DOWNGRADE
Target $92
CHLM
Hold
LHC Group downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Kevin Ellich downgraded LHC Group to Hold from Buy and lowered his price target to $92 from $99, telling investors in a research note that he believes uncertainty related to the potential rate cut in 2020 from Medicare's proposed Patient-Driven Groupings Model will remain an overhang on shares. While the final 2019 Medicare Home Health rule should be released in the coming days, the analyst does not expect any major changes from the proposed rule and uncertainty related to PDGM will likely keep shares of LHC Group range-bound in the near-term, especially with the stock trading at a hefty premium to its historical averages. Further, Ellich says that while he expects "solid" Q3 results and believe the integration of Almost Family is likely going well, he thinks guidance will be maintained and that Q4 consensus EPS appears "off due to the sharp increase in share count attributable to the Almost Family deal."
10/26/18
CHLM
10/26/18
DOWNGRADE
CHLM
Hold
LHC Group downgraded to Hold from Buy at Craig-Hallum
HCA HCA Healthcare
$137.72

-2.14 (-1.53%)

10/31/18
OPCO
10/31/18
NO CHANGE
Target $142
OPCO
Outperform
HCA Healthcare price target raised to $142 from $130 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for HCA Healthcare to $142 from $130 following quarterly results. The analyst believes HCA continues to produce "impressive and stable results" as it successfully navigates through the challenges facing the hospital industry. He reiterates an Outperform rating on the shares.
11/01/18
FBCO
11/01/18
NO CHANGE
Target $165
FBCO
Outperform
HCA Healthcare price target raised to $165 from $156 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for HCA Healthcare to $165 from $156 following quarterly results. The analyst reiterates an Outperform rating on the shares.
11/07/18
MSCO
11/07/18
NO CHANGE
MSCO
Split Congress 'best outcome' for MCOs and hospitals, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak contends that the Democratic party retaking the majority in the House of Representatives and Republicans retaining the Senate is the "best outcome" for Managed Care Organizations and hospitals, stating that he now sees another attempt at a repeal/replace of the Affordable Care Act as "off the table." The split Congress could also lower the volume on the "Medicare for All" debate given a lack of mandate from either the Democratic or Republican party, Sopcak tells investors. The election results remove a key overhang for Centene (CNC) and Molina (MOH), which he views as most exposed to the ACA marketplace, and to a lesser extent the hospitals, Sopcak added. With ACA repeal/replace off the table, and given the longer term potential upside from Medicaid expansion in Utah and Idaho as expansion ballot initiatives appear to be passing in both states, Sopcak said Molina is emerging as his top pick in the space heading into the final weeks of 2018. Publicly traded hospital companies include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
11/15/18
UBSW
11/15/18
INITIATION
Target $162
UBSW
Buy
HCA Healthcare initiated with a Buy at UBS
UBS analyst Whit Mayo initiated HCA Healthcare with a Buy rating and a price target of $162.
THC Tenet
$23.70

-0.04 (-0.17%)

08/14/18
LEHM
08/14/18
INITIATION
LEHM
Barclays starts Hospital sector with Neutral outlook, top pick HCA
Barclays analyst Steve Valiquette initiated coverage of the Hospital sector with a Neutral rating. Operators continue to face incremental pressures from alternative payment models that are shifting incentives towards lower-cost sites of care, Valiquette tells investors in a research note. He believes, however, that despite industry headwinds, operators levered to markets with high population growth and high relative market share will continue to outperform the industry. The analyst's only Overweight rated name in space is HCA Healthcare (HCA). The analyst initiated coverage of HCA with an Overweight rating and $150 price target. He sees HCA as well positioned in local markets. Valiquette also started Universal Health Services (UHS) and Tenet Healthcare (THC) with Equal Weight ratings. His lone Underweight rating is put on Community Health Systems (CYH). The company is still burdened with excessive debt and constrained free cash flow from its rural hospital footprint, Valiquette contends.
08/14/18
LEHM
08/14/18
INITIATION
Target $35
LEHM
Equal Weight
Tenet initiated with an Equal Weight at Barclays
Barclays analyst Steven Valiquette started Tenet Healthcare with an Equal Weight rating and $35 price target.
11/15/18
UBSW
11/15/18
INITIATION
Target $26
UBSW
Neutral
Tenet initiated with a Neutral at UBS
UBS analyst Whit Mayo initiated Tenet with a Neutral rating and a price target of $26.
SGRY Surgery Partners
$13.63

0.01 (0.07%)

09/18/18
BOFA
09/18/18
UPGRADE
Target $20
BOFA
Buy
Surgery Partners upgraded to Buy on volume turnaround at BofA/Merrill
As previously reported, BofA/Merrill upgraded Surgery Partners to Buy from Neutral and maintained a $20 price target. Analyst Kevin Fischbeck believes Surgery Partners' volume turnaround is near an inflection point and expects growth to improve through 2018 and 2019.
11/15/18
UBSW
11/15/18
INITIATION
Target $15
UBSW
Neutral
Surgery Partners initiated with a Neutral at UBS
UBS analyst Whit Mayo initiated Surgery Partners with a Neutral rating and a price target of $15.
08/13/18
LEER
08/13/18
NO CHANGE
Target $25
LEER
Outperform
Surgery Partners price target raised to $25 from $20 at Leerink
Leerink analyst Ana Gupte raised her price target for Surgery Partners to $25 from $20 as she has increased conviction on its EBITDA growth and margin expansion opportunity. The analyst reiterates an Outperform rating on the shares.
09/18/18
BOFA
09/18/18
UPGRADE
BOFA
Buy
Surgery Partners upgraded to Buy from Neutral at BofA/Merrill
AMED Amedisys
$121.97

4.88 (4.17%)

10/30/18
BNCH
10/30/18
UPGRADE
BNCH
Buy
Amedisys upgraded to Buy from Hold at Benchmark
10/30/18
10/30/18
UPGRADE
Target $125

Buy
Amedisys upgraded to Buy after 'beat and raise' report at Benchmark
As previously reported, Benchmark analyst Bill Sutherland upgraded Amedisys to Buy from Hold after the company posted what he called "another strong beat" in Q3 and lifted its full year 2018 guidance for a second time. While the stock is down nearly 30% from recent highs, the intermediate outlook has actually improved, Sutherland tells investors. He also contends that Amedisys' "growing appeal to a financial or strategic buyer" supports a premium valuation. Sutherland set a $125 price target on Amedisys shares.
11/15/18
UBSW
11/15/18
INITIATION
Target $126
UBSW
Neutral
Amedisys initiated with a Neutral at UBS
UBS analyst Whit Mayo initiated Amedisys with a Neutral rating and a price target of $126.
10/30/18
JEFF
10/30/18
NO CHANGE
Target $140
JEFF
Buy
Amedisys pullback brings good entry point, says Jefferies
Jefferies analyst Brian Tanquilut remains bullish on Amedisys following the company's Q3 results and believes the recent share pullback provides a good entry point. The upside in the quarter underscores continued strength of the company's fundamentals, Tanquilut tells investors in a post-earnings research note. He believes the Amedisys is "poised to deliver robust earnings growth in 2019 and beyond," driven by organic acceleration in both the Medicare and Medicare Advantage businesses and management's disciplined capital deployment strategy. Tanquilut keeps a Buy rating on the shares with a $140 price target.
ACHC Acadia
$37.85

0.37 (0.99%)

11/15/18
UBSW
11/15/18
INITIATION
Target $39
UBSW
Neutral
Acadia initiated with a Neutral at UBS
UBS analyst Whit Mayo initiated Acadia with a Neutral rating and a price target of $39.
DVA DaVita
$64.64

0.26 (0.40%)

11/15/18
UBSW
11/15/18
INITIATION
Target $64
UBSW
Sell
DaVita initiated with a Sell at UBS
UBS analyst Whit Mayo initiated DaVita with a Sell rating and a price target of $64.
11/08/18
RAJA
11/08/18
DOWNGRADE
RAJA
Market Perform
DaVita downgraded to Market Perform from Strong Buy at Raymond James
Raymond James analyst John Ransom downgraded DaVita two notches to Market Perform from Strong Buy citing valuation and lack of catalysts.
09/13/18
09/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Hold from Sell at Pivotal Research with analyst Brian Wieser saying risks are still present, especially in the near-term, but current trading levels balance those risks with the company' long-term potential. 2. DaVita (DVA) upgraded to Neutral from Underweight at JPMorgan with analyst Gary Taylor saying he now believes is it much more likely that California Governor Brown will veto the recently passed SB1156, which he notes would curtail the financial arbitrage that dialysis providers enjoy from charitable premium assistance. 3. Intel (INTC) upgraded to Market Perform from Underperform at Northland with analyst Auguste Richard saying the stock has corrected 23% from its 52-week high and is down 20% since mid-June. 4. Magna (MGA) upgraded to Outperformer from Neutral at CIBC. 5. Flowserve (FLS) upgraded to Buy from Neutral at Northcoast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/18
JPMS
09/13/18
UPGRADE
Target $68
JPMS
Neutral
JPMorgan upgrades DaVita to Neutral on better chance of SB1156 veto
JPMorgan analyst Gary Taylor upgraded DaVita to Neutral from Underweight with an unchanged price target of $68. The analyst now believes is it much more likely that California Governor Brown will veto the recently passed SB1156, which he notes would curtail the financial arbitrage that dialysis providers enjoy from charitable premium assistance. With shares of DaVita down nearly 10% since the bill's passage, the analyst sees "better prospects for the stock to recover that ground" in the near-term. As such, he views the company's risk/reward as more balanced at current share levels. However, Taylor retains his longer-term concern regarding the charitable premium assistance "cat & mouse" game between employers/insurers and dialysis providers.
MD Mednax
$39.81

-0.03 (-0.08%)

09/24/18
LEER
09/24/18
UPGRADE
LEER
Outperform
Mednax upgraded to Outperform from Market Perform at Leerink
09/24/18
09/24/18
UPGRADE
Target $56

Outperform
Mednax upgraded to Outperform as turnaround continues at Leerink
As previously reported, Leerink analyst Ana Gupte upgraded Mednax to Outperform from Market Perform on the margin turnaround, improving neonatal share gains despite flattish secular demand, and the selloff post Elliott news on Friday which she views as a buying opportunity. The analyst also raised her price target on the shares to $56 from $52.
11/06/18
FBCO
11/06/18
NO CHANGE
Target $50
FBCO
Outperform
Mednax price target lowered to $50 from $55 at Credit Suisse
Credit Suisse analyst A.J. Rice lowered his price target for Mednax to $50 from $55, while reiterating an Outperform rating on the shares. The analyst notes that the company has announced the decision to pursue a sale of its MedData segment.
11/15/18
UBSW
11/15/18
INITIATION
Target $37
UBSW
Sell
Mednax initiated with a Sell at UBS
UBS analyst Whit Mayo initiated Mednax with a Sell rating and a price target of $37.
CYH Community Health
$3.59

-0.11 (-2.97%)

11/15/18
UBSW
11/15/18
INITIATION
Target $2
UBSW
Sell
Community Health initiated with a Sell at UBS
UBS analyst Whit Mayo initiated Community Health with a Sell rating and a price target of $2.
10/31/18
CANT
10/31/18
NO CHANGE
Target $4
CANT
Neutral
Community Health price target lowered to $4 from $6 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph France lowered his price target for Community Health Systems to $4 citing reduced long-term growth expectations and a higher discount rate to account for a slower pace of debt reduction. The reported slightly higher than expected revenue and earnings , but the upside reflects delays in completing divestitures, because volumes are soft, France tells investors in a post-earnings research note. He keeps a Neutral rating on Community Health.

TODAY'S FREE FLY STORIES

MHK

Mohawk

$123.49

5 (4.22%)

10:45
12/19/18
12/19
10:45
12/19/18
10:45
Downgrade
Mohawk rating change  »

Mohawk downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$158.32

3.66 (2.37%)

10:44
12/19/18
12/19
10:44
12/19/18
10:44
Hot Stocks
Route1 files patent infringement complaint against VMware, AirWatch »

Route1 announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

CI

Cigna

$192.93

0.83 (0.43%)

, ESRX

Express Scripts

$95.33

0.31 (0.33%)

10:44
12/19/18
12/19
10:44
12/19/18
10:44
Hot Stocks
Cigna, Express Scripts receive approval from state of NJ for merger transaction »

In a regulatory filing,…

CI

Cigna

$192.93

0.83 (0.43%)

ESRX

Express Scripts

$95.33

0.31 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

GM

General Motors

$35.68

0.77 (2.21%)

10:40
12/19/18
12/19
10:40
12/19/18
10:40
Options
Far upside call buyer in GM »

Far upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMD

Cantel Medical

$75.82

-0.35 (-0.46%)

10:37
12/19/18
12/19
10:37
12/19/18
10:37
Hot Stocks
Cantel Medical raises semiannual dividend 17.6% to 10c per share »

Cantel Medical Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$257.42

2.33 (0.91%)

10:32
12/19/18
12/19
10:32
12/19/18
10:32
Periodicals
Senate to introduce short-term measure to avoid government shutdown, CNBC says »

The Senate will introduce…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$257.42

2.33 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:31
12/19/18
12/19
10:31
12/19/18
10:31
General news
Crude inventories for week of December 14 »

Crude oil inventories…

ABX

Barrick Gold

$13.82

-0.07 (-0.50%)

10:30
12/19/18
12/19
10:30
12/19/18
10:30
Options
Heavy volume in Barrick Gold downside Jan puts »

Heavy volume in Barrick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JKS

JinkoSolar

$10.99

-0.05 (-0.45%)

10:29
12/19/18
12/19
10:29
12/19/18
10:29
Initiation
JinkoSolar initiated  »

JinkoSolar initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Dec

10:25
12/19/18
12/19
10:25
12/19/18
10:25
General news
Treasury Action: flattening is the trade ahead of the FOMC »

Treasury Action:…

10:25
12/19/18
12/19
10:25
12/19/18
10:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

10:25
12/19/18
12/19
10:25
12/19/18
10:25
Conference/Events
UBS retail analyst to hold an analyst/industry conference call »

Retail Analyst Sole…

10:20
12/19/18
12/19
10:20
12/19/18
10:20
General news
FX Action: The dollar »

FX Action: The dollar…

SPY

SPDR S&P 500 ETF Trust

$257.02

1.93 (0.76%)

10:20
12/19/18
12/19
10:20
12/19/18
10:20
Options
Size ratio spread in SPYders weekly options »

Size ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
12/19/18
12/19
10:20
12/19/18
10:20
General news
Treasury Action: yields remained pinned lower »

Treasury Action: yields…

ULTA

Ulta Beauty

$245.00

4.07 (1.69%)

, MTCH

Match Group

$42.58

0.6 (1.43%)

10:19
12/19/18
12/19
10:19
12/19/18
10:19
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

ULTA

Ulta Beauty

$245.00

4.07 (1.69%)

MTCH

Match Group

$42.58

0.6 (1.43%)

SSTI

ShotSpotter

$30.30

1.12 (3.84%)

OKTA

Okta

$66.09

3.32 (5.29%)

CLLS

Cellectis

$18.35

0.6 (3.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

  • 09

    Jan

  • 16

    Jan

ALKS

Alkermes

$31.58

-0.25 (-0.79%)

, ADI

Analog Devices

$87.50

-0.57 (-0.65%)

10:19
12/19/18
12/19
10:19
12/19/18
10:19
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

ALKS

Alkermes

$31.58

-0.25 (-0.79%)

ADI

Analog Devices

$87.50

-0.57 (-0.65%)

UAA

Under Armour

$18.63

-0.18 (-0.96%)

UA

Under Armour

$17.21

-0.18 (-1.04%)

MU

Micron

$33.30

-0.82 (-2.40%)

JPM

JPMorgan

$99.31

0.79 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 08

    Jan

  • 08

    Jan

  • 31

    Jan

  • 26

    Feb

  • 03

    Mar

MDT

Medtronic

$92.20

0.18 (0.20%)

, MASI

Masimo

$106.37

1.08 (1.03%)

10:19
12/19/18
12/19
10:19
12/19/18
10:19
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

MDT

Medtronic

$92.20

0.18 (0.20%)

MASI

Masimo

$106.37

1.08 (1.03%)

DRI

Darden

$103.74

-0.08 (-0.08%)

BBY

Best Buy

$52.56

0.57 (1.10%)

GE

General Electric

$7.78

0.505 (6.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
12/19/18
12/19
10:17
12/19/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
12/19/18
12/19
10:16
12/19/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
12/19/18
12/19
10:15
12/19/18
10:15
General news
U.S. existing home sales rose 1.9% to 5.320 M in November »

U.S. existing home sales…

10:15
12/19/18
12/19
10:15
12/19/18
10:15
General news
Breaking General news story  »

Week of 12/14 EIA…

XLU

Utilities SPDR

$54.42

-0.21 (-0.38%)

10:10
12/19/18
12/19
10:10
12/19/18
10:10
Options
18.8K SPDR Utility Fund Dec 51 - 53 put spreads trade 12c »

18.8K SPDR Utility Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FND

Floor & Decor

$26.63

0.09 (0.34%)

10:06
12/19/18
12/19
10:06
12/19/18
10:06
Recommendations
Floor & Decor analyst commentary  »

Morgan Stanley says Floor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWA

BorgWarner

$35.14

0.73 (2.12%)

10:05
12/19/18
12/19
10:05
12/19/18
10:05
Hot Stocks
BorgWarner extends agreement to be Official Turbocharger Partner of INDYCAR »

BorgWarner and INDYCAR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.